Dual Activation of TRIF and MyD88 Adaptor Proteins by Angiotensin II Evokes Opposing Effects on Pressure, Cardiac Hypertrophy, and Inflammatory Gene Expression

Hypertension

Volumn 66, Issue 3, 2015, Pages 647-656

  Singh, Madhu V ^a   Cicha, Michael Z ^b   Meyerholz, David K ^a   Chapleau, Mark W ^a,b   Abboud, François M ^a  

^a UNIVERSITY OF IOWA   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

angiotensin II; gene expression; hypertension; MyD88 protein; TICAM 1 protein; toll like receptors

Indexed keywords

ADAPTOR PROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN TYPE 1A RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RNA; TOLL INTERLEUKIN RECEPTOR DOMAIN CONTAINING ADAPTOR PROTEIN INDUCING INTERFERON BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MYD88 PROTEIN, MOUSE; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL HYPERTENSION; EXPERIMENTAL INFLAMMATION; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; HEART; HEART VENTRICLE HYPERTROPHY; INNATE IMMUNITY; KIDNEY; MALE; MOUSE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WILD TYPE; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; DRUG EFFECTS; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; GENE EXPRESSION; INFLAMMATION; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88;

EID: 84939225940     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06011     Document Type: Article

References (70)

1. Singh MV, Abboud FM. Toll-like receptors and hypertension. Am J Physiol Regul Integr Comp Physiol. 2014;307:R501-R504. doi: 10.1152/ ajpregu.00194.2014.
2. Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunol Res. 2014;59:243-253. doi: 10.1007/ s12026-014-8548-6.
3. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-140. doi: 10.1161/HYPERTENSIONAHA.110.163576.
4. Harrison DG, Vinh A, Lob H, Madhur MS. Role of the adaptive immune system in hypertension. Curr Opin Pharmacol. 2010;10:203-207. doi: 10.1016/j.coph.2010.01.006.
5. Rodríguez-Iturbe B, Pons H, Quiroz Y, Lanaspa MA, Johnson RJ. Autoimmunity in the pathogenesis of hypertension. Nat Rev Nephrol. 2014;10:56-62. doi: 10.1038/nrneph.2013.248.
6. Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29:543-548. doi: 10.1016/j.cjca.2012.06.009.
7. Mian MO, Paradis P, Schiffrin EL. Innate immunity in hypertension. Curr Hypertens Rep. 2014;16:413. doi: 10.1007/s11906-013-0413-9.
8. Ryan MJ. An update on immune system activation in the pathogenesis of hypertension. Hypertension. 2013;62:226-230. doi: 10.1161/ HYPERTENSIONAHA.113.00603.
9. Rudemiller N, Lund H, Jacob HJ, Geurts AM, Mattson DL; PhysGen Knockout Program. CD247 modulates blood pressure by altering T-lymphocyte infiltration in the kidney. Hypertension. 2014;63:559-564. doi: 10.1161/HYPERTENSIONAHA.113.02191.
10. Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu Y, Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC, Li H. Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension. 2013;61:1193-1202. doi: 10.1161/HYPERTENSIONAHA.111.00614.
11. Quiroz Y, Johnson RJ, Rodriguez-Iturbe B. The role of T cells in the pathogenesis of primary hypertension. Nephrol Dial Transplant. 2012;27(Suppl 4):iv2-5.
12. Matrougui K, Abd Elmageed Z, Zakaria AE, Kassan M, Choi S, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Kadowitz P, Belmadani S, Partyka M. Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol. 2011;178:434-441. doi: 10.1016/j.ajpath.2010.11.034.
13. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460. doi: 10.1084/jem.20070657.
14. Yu Q, Horak K, Larson DF. Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertension. 2006;48:98-104. doi: 10.1161/01.HYP.0000227247.27111.b2.
15. Ba D, Takeichi N, Kodama T, Kobayashi H. Restoration of T cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts. J Immunol. 1982;128:1211-1216.
16. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59:755-762. doi: 10.1161/ HYPERTENSIONAHA.111.186833.
17. Harwani SC, Chapleau MW, Legge KL, Ballas ZK, Abboud FM. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res. 2012;111:1190-1197. doi: 10.1161/CIRCRESAHA.112.277475.
18. Zubcevic J, Waki H, Raizada MK, Paton JF. Autonomic-immunevascular interaction: an emerging concept for neurogenic hypertension. Hypertension. 2011;57:1026-1033. doi: 10.1161/ HYPERTENSIONAHA.111.169748.
19. Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, Fortes ZB, Webb RC, Carvalho MH. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond). 2012;122:535-543. doi: 10.1042/CS20110523.
20. Dange RB, Agarwal D, Masson GS, Vila J, Wilson B, Nair A, Francis J. Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res. 2014;103:17-27. doi: 10.1093/cvr/cvu067.
21. Coble JP, Grobe JL, Johnson AK, Sigmund CD. Mechanisms of brain renin angiotensin system-induced drinking and blood pressure: importance of the subfornical organ. Am J Physiol Regul Integr Comp Physiol. 2015;308:R238-R249. doi: 10.1152/ajpregu.00486.2014.
22. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014;16:431. doi: 10.1007/ s11906-014-0431-2.
23. Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol. 2011;11:180-186. doi: 10.1016/j.coph.2011.01.009.
24. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73:413-423.
25. Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ. 2014;38:20-24. doi: 10.1152/advan.00063.2013.
26. Moresco EM, LaVine D, Beutler B. Toll-like receptors. Curr Biol. 2011;21:R488-R493. doi: 10.1016/j.cub.2011.05.039.
27. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353-364. doi: 10.1038/nri2079.
28. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine. 2008;43:342-349. doi: 10.1016/j.cyto.2008.07.010.
29. Siednienko J, Halle A, Nagpal K, Golenbock DT, Miggin SM. TLR3-mediated IFN- gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like. Eur J Immunol. 2010;40:3150-3160. doi: 10.1002/eji.201040547.
30. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-190. doi: 10.1038/ nri2038.
31. Re F, Strominger JL. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol. 2004;173:7548-7555.
32. Singh MV, Swaminathan PD, Luczak ED, Kutschke W, Weiss RM, Anderson ME. MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol. 2012;52:1135-1144. doi: 10.1016/j.yjmcc.2012.01.021.
33. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature. 2003;424:743-748. doi: 10.1038/nature01889.
34. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 1998;9:143-150.
35. Gibson-Corley KN, Olivier AK, Meyerholz DK. Principles for valid histopathologic scoring in research. Vet Pathol. 2013;50:1007-1015. doi: 10.1177/0300985813485099.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. doi: 10.1006/meth.2001.1262.
37. Singh MV, Kapoun A, Higgins L, et al. Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart. J Clin Invest. 2009;119:986-996. doi: 10.1172/JCI35814.
38. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 1998;98:794-799.
39. Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51:1345-1351. doi: 10.1161/HYPERTENSIONAHA.107.102152.
40. Gomolak JR, Didion SP. A role for innate immunity in the development of hypertension. Med Hypotheses. 2014;83:640-643. doi: 10.1016/j. mehy.2013.12.027.
41. Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, Liu CY, Sun T, Zhang XJ, Li PF. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res. 2014;114:1377-1388. doi: 10.1161/CIRCRESAHA.114.302476.
42. Gomolak JR, Faulkner JL and Didion SP. Myeloid differentiation Factor 88 (MyD88) does not contribute to hypertension or endothelial dysfunction produced by angiotensin II. FASEB J. 2013;27:1131.15.
43. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
44. Zhang J, Patel MB, Griffiths R, Mao A, Song YS, Karlovich NS, Sparks MA, Jin H, Wu M, Lin EE, Crowley SD. Tumor necrosis factor- produced in the kidney contributes to angiotensin II-dependent hypertension. Hypertension. 2014;64:1275-1281. doi: 10.1161/ HYPERTENSIONAHA.114.03863.
45. Kim SM, Kim YG, Jeong KH, Lee SH, Lee TW, Ihm CG, Moon JY. Angiotensin II-induced mitochondrial Nox4 is a major endogenous source of oxidative stress in kidney tubular cells. PLoS One. 2012;7:e39739. doi: 10.1371/journal.pone.0039739.
46. Mollnau H, Wendt M, Szöcs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58-E65.
47. Matsushima S, Kuroda J, Ago T, Zhai P, Park JY, Xie LH, Tian B, Sadoshima J. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res. 2013;112:651-663. doi: 10.1161/CIRCRESAHA.112.279760.
48. Zeng SY, Chen X, Chen SR, Li Q, Wang YH, Zou J, Cao WW, Luo JN, Gao H, Liu PQ. Upregulation of Nox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression. Can J Cardiol. 2013;29:1310-1319. doi: 10.1016/j.cjca.2013.04.026.
49. Zhao QD, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X, Bhandari B, Abboud HE. NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFB signaling pathways. Circulation. 2015;131:643-655. doi: 10.1161/CIRCULATIONAHA.114.011079.
50. Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24-32. doi: 10.1016/j.smim.2006.12.004.
51. West AP, Koblansky AA, Ghosh S. Recognition and signaling by tolllike receptors. Annu Rev Cell Dev Biol. 2006;22:409-437. doi: 10.1146/ annurev.cellbio.21.122303.115827.
52. Björkbacka H, Fitzgerald KA, Huet F, Li X, Gregory JA, Lee MA, Ordija CM, Dowley NE, Golenbock DT, Freeman MW. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics. 2004;19:319-330. doi: 10.1152/physiolgenomics.00128.2004.
53. Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T, Rao G, Sun R, Haberland M, Modlin R, Cheng G. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 2002;17:251-263.
54. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749-3752.
55. Kawai T, Takeuchi O, Fujita T, Inoue J, Mühlradt PF, Sato S, Hoshino K, Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 2001;167:5887-5894.
56. Wang E, Feng Y, Zhang M, Zou L, Li Y, Buys ES, Huang P, Brouckaert P, Chao W. Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase-and soluble guanylate cyclase-dependent mechanisms. Anesthesiology. 2011;114:603-613. doi: 10.1097/ALN.0b013e31820a4d5b.
57. Gobert AP, Bambou JC, Werts C, Balloy V, Chignard M, Moran AP, Ferrero RL. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem. 2004;279:245-250. doi: 10.1074/jbc.M307858200.
58. Cotroneo TM, Nemzek-Hamlin JA, Bayliss J, Su GL. Lipopolysaccharide binding protein inhibitory peptide alters hepatic inflammatory response post-hemorrhagic shock. Innate Immun. 2012;18:866-875. doi: 10.1177/1753425912444641.
59. Lang T, Mansell A. The negative regulation of Toll-like receptor and associated pathways. Immunol Cell Biol. 2007;85:425-434. doi: 10.1038/ sj.icb.7100094.
60. Datta De D, Datta A, Bhattacharjya S, Roychoudhury S. NF-kappaB mediated transcriptional repression of acid modifying hormone gastrin. PLoS One. 2013;8:e73409. doi: 10.1371/journal.pone.0073409.
61. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol. 2001;21:7065-7077. doi: 10.1128/MCB.21.20.7065-7077.2001.
62. Baetz D, Regula KM, Ens K, Shaw J, Kothari S, Yurkova N, Kirshenbaum LA. Nuclear factor-kappaB-mediated cell survival involves transcriptional silencing of the mitochondrial death gene BNIP3 in ventricular myocytes. Circulation. 2005;112:3777-3785. doi: 10.1161/ CIRCULATIONAHA.105.573899.
63. Selvarajoo K, Takada Y, Gohda J, Helmy M, Akira S, Tomita M, Tsuchiya M, Inoue J, Matsuo K. Signaling flux redistribution at toll-like receptor pathway junctions. PLoS One. 2008;3:e3430. doi: 10.1371/journal.pone.0003430.
64. Obonyo M, Sabet M, Cole SP, Ebmeyer J, Uematsu S, Akira S, Guiney DG. Deficiencies of myeloid differentiation factor 88, Toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori. Infect Immun. 2007;75:2408-2414. doi: 10.1128/IAI.01794-06.
65. Johnson AC, Li X, Pearlman E. MyD88 functions as a negative regulator of TLR3/TRIF-induced corneal inflammation by inhibiting activation of c-Jun N-terminal kinase. J Biol Chem. 2008;283:3988-3996. doi: 10.1074/jbc.M707264200.
66. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
67. Chang J, Kunkel SL, Chang CH. Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Proc Natl Acad Sci U S A. 2009;106:18327-18332. doi: 10.1073/pnas.0905815106.
68. Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110:191-202.
69. Turer EE, Tavares RM, Mortier E, Hitotsumatsu O, Advincula R, Lee B, Shifrin N, Malynn BA, Ma A. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med. 2008;205:451-464. doi: 10.1084/jem.20071108.
70. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290:H935-H940. doi: 10.1152/ajpheart.00708.2005.